Efficacy and Safety of Poziotinib in HER2 Exon 20 Insertion NSCLC Patients who Received at Least 2 Previous Systemic Therapies

被引：0
|
作者：
Le, X. [1 ]
Prelaj, A. [2 ]
Baik, C. [3 ]
Tchekmedyian, N. [4 ]
Leu, S. [5 ]
Bhat, G. [5 ]
Heymach, J. V. [1 ]
Cornelissen, R. [6 ]
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Ist Nazl Tumori Milano Fdn IRCCS, Milan, Italy
[3] Seattle Canc Ctr Alliance, Seattle, WA USA
[4] City Hope Natl Med Ctr, Irvine, CA USA
[5] Spectrum Pharmaceut, Irvine, CA USA
[6] Erasmus MC Canc Inst, Rotterdam, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
HER2; exon20; poziotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA13.09
引用
收藏
页码：S147 / S148
页数：2
相关论文
共 50 条
  • [41] Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab
    Passaro, A.
    Yu, H. A.
    Nguyen, D.
    Lee, V. H. F.
    Soo, R. A.
    Kim, S. H.
    Daga, H.
    Tan, D. S. W.
    Kim, S-W.
    Juan Vidal, O. J.
    Piotrowska, Z.
    Keeton, E. K.
    Liu, T.
    Li, S.
    Jones, J.
    Ruiter, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S803 - S804
  • [42] Discovery of potent, selective, and orally bioavailable HER2 tyrosine kinase inhibitors targeting HER2 exon20 insertion mutants and HER2WT
    Yoo, H. S.
    Jang, S. Y.
    Jeon, J.
    Nam, H. Y.
    Byun, J.
    Lee, G.
    Jeon, S.
    Chon, H.
    Kim, Y. Y.
    Park, H.
    An, Y. G.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S44 - S45
  • [43] Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling
    Birgit Wilding
    Dirk Scharn
    Dietrich Böse
    Anke Baum
    Valeria Santoro
    Paolo Chetta
    Renate Schnitzer
    Dana A. Botesteanu
    Christoph Reiser
    Stefan Kornigg
    Petr Knesl
    Alexandra Hörmann
    Anna Köferle
    Maja Corcokovic
    Simone Lieb
    Guido Scholz
    Jens Bruchhaus
    Markus Spina
    Josef Balla
    Biljana Peric-Simov
    Jasmin Zimmer
    Sophie Mitzner
    Thomas N. Fett
    Alexandra Beran
    Lyne Lamarre
    Thomas Gerstberger
    Daniel Gerlach
    Markus Bauer
    Andreas Bergner
    Andreas Schlattl
    Gerd Bader
    Matthias Treu
    Harald Engelhardt
    Stephan Zahn
    Julian E. Fuchs
    Johannes Zuber
    Peter Ettmayer
    Mark Pearson
    Mark Petronczki
    Norbert Kraut
    Darryl B. McConnell
    Flavio Solca
    Ralph A. Neumüller
    Nature Cancer, 2022, 3 : 821 - 836
  • [44] Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens
    Azadeh Nasrazadani
    Juan Luis Gomez Marti
    Kate Lathrop
    Alvaro Restrepo
    Szu-Yun Leu
    Gajanan Bhat
    Adam Brufsky
    Breast Cancer Research and Treatment, 2024, 205 : 29 - 37
  • [45] Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling
    Wilding, Birgit
    Scharn, Dirk
    Boese, Dietrich
    Baum, Anke
    Santoro, Valeria
    Chetta, Paolo
    Schnitzer, Renate
    Botesteanu, Dana A.
    Reiser, Christoph
    Kornigg, Stefan
    Knesl, Petr
    Hoermann, Alexandra
    Koeferle, Anna
    Corcokovic, Maja
    Lieb, Simone
    Scholz, Guido
    Bruchhaus, Jens
    Spina, Markus
    Balla, Josef
    Peric-Simov, Biljana
    Zimmer, Jasmin
    Mitzner, Sophie
    Fett, Thomas N.
    Beran, Alexandra
    Lamarre, Lyne
    Gerstberger, Thomas
    Gerlach, Daniel
    Bauer, Markus
    Bergner, Andreas
    Schlattl, Andreas
    Bader, Gerd
    Treu, Matthias
    Engelhardt, Harald
    Zahn, Stephan
    Fuchs, Julian E.
    Zuber, Johannes
    Ettmayer, Peter
    Pearson, Mark
    Petronczki, Mark
    Kraut, Norbert
    McConnell, Darryl B.
    Solca, Flavio
    Neumuller, Ralph A.
    NATURE CANCER, 2022, 3 (07) : 821 - +
  • [46] Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens
    Nasrazadani, Azadeh
    Marti, Juan Luis Gomez
    Lathrop, Kate
    Restrepo, Alvaro
    Leu, Szu-Yun
    Bhat, Gajanan
    Brufsky, Adam
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 205 (01) : 29 - 37
  • [47] Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 overexpressing cancers who have received a HER2 vaccine
    Disis, M. L.
    Salazar, L. G.
    Coveler, A.
    Waisman, J.
    Higgins, D.
    Childs, J.
    Bates, N.
    Dang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yamamoto, N.
    Yoh, K.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S421 - S422
  • [49] Structure optimization and discovery of novel compound for the treatment of insertion mutations within exon 20 of EGFR and HER2
    Cui, Yetong
    Wang, Ruonan
    Wei, Yujiao
    Hou, Fei
    Li, Haixi
    Jiang, Yurui
    Sun, Yue
    Fu, Shushu
    Zuo, Lina
    Wang, Xiaoji
    Li, Ming
    Li, Jinling
    Liu, Ning
    Zhang, Kun
    Wei, Mingming
    Yang, Guang
    BIOORGANIC & MEDICINAL CHEMISTRY, 2023, 81
  • [50] Targeting HER2 or EGFR Exon 20 Insertion Mutation in Lung Cancer - A Case Series from India
    Varughese, V. J.
    Joseph, S.
    Sirohi, B.
    Raut, N.
    Mathew, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1117 - S1117
12345